Sfoglia per Autore
Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out
2019-01-01 Proto, C.; Ferrara, R.; Signorelli, D.; Lo Russo, G.; Galli, G.; Imbimbo, M.; Prelaj, A.; Zilembo, N.; Ganzinelli, M.; Pallavicini, L. M.; De Simone, I.; Colombo, M. P.; Sica, A.; Torri, V.; Garassino, M. C.
The Prognostic Role of TNM Staging Compared With Tumor Volume and Number of Pleural Sites in Malignant Pleural Mesothelioma
2019-01-01 Proto, C.; Signorelli, D.; Mallone, S.; Prelaj, A.; Lo Russo, G.; Imbimbo, M.; Galli, G.; Ferrara, R.; Ganzinelli, M.; Leuzzi, G.; Greco, F. G.; Calareso, G.; Botta, L.; Gatta, G.; Garassino, M.; Trama, A.
Epsilon: A prognostic score for immunotherapy in advanced non-small-cell lung cancer: A validation cohort
2019-01-01 Prelaj, A.; Ferrara, R.; Rebuzzi, S. E.; Proto, C.; Signorelli, D.; Galli, G.; De Toma, A.; Randon, G.; Pagani, F.; Viscardi, G.; Brambilla, M.; Trevisan, B.; Ganzinelli, M.; Martinetti, A.; Gallucci, R.; Di Mauro, R. M.; Molino, G.; Zilembo, N.; Torri, V.; de Braud, F. M.; Garassino, M. C.; Lo Russo, G.
Is there an interplay between immune checkpoint inhibitors, thromboprophylactic treatments and thromboembolic events? Mechanisms and impact in non-small cell lung cancer patients
2019-01-01 Nichetti, F.; Ligorio, F.; Zattarin, E.; Signorelli, D.; Prelaj, A.; Proto, C.; Galli, G.; Marra, A.; Apollonio, G.; Porcu, L.; de Braud, F.; Lo Russo, G.; Ferrara, R.; Garassino, M. C.
Efficacy and safety of immunotherapy in elderly patients with non-small cell lung cancer
2019-01-01 Galli, G.; De Toma, A.; Pagani, F.; Randon, G.; Trevisan, B.; Prelaj, A.; Ferrara, R.; Proto, C.; Signorelli, D.; Ganzinelli, M.; Zilembo, N.; de Braud, F.; Garassino, M. C.; Lo Russo, G.
Characterization of patients with metastatic non-small-cell lung cancer obtaining long-term benefit from immunotherapy
2019-01-01 Galli, G.; Proto, C.; Signorelli, D.; Imbimbo, M.; Ferrara, R.; Prelaj, A.; De Toma, A.; Ganzinelli, M.; Zilembo, N.; De Braud, F.; Garassino, M. C.; Lo Russo, G.
ALK/ROS1 rearrangements: A real hallmark for thromboembolic events in cancer patients?
2020-01-01 Nichetti, F.; Russo, G. L.; Prelaj, A.; Provenzano, L.; de Braud, F.; Cabiddu, M.; Garassino, M. C.; Petrelli, F.
SMO mutations confer poor prognosis in malignant pleural mesothelioma
2020-01-01 Signorelli, D.; Proto, C.; Botta, L.; Trama, A.; Tiseo, M.; Pasello, G.; Russo, G. L.; Fabbri, A.; Imbimbo, M.; Busico, A.; Prelaj, A.; Ferrara, R.; Galli, G.; de Toma, A.; Tamborini, E.; Pastorino, U.; de Braud, F.; Gatta, G.; Garassino, M. C.; Ganzinelli, M.
Integrating clinical and biological prognostic biomarkers in patients with advanced NSCLC treated with immunotherapy: the DEMo score system
2020-01-01 Prelaj, A; Proto, C; Lo Russo, G; Signorelli, D; Ferrara, R; Mensah, M; Galli, G; De Toma, A; Viscardi, G; Brambilla, M; Lobefaro, R; Trevisan, B; Trovo, F; Torri, V; Sozzi, G; Garassino, Mc; Boeri, M
DiM: Prognostic Score for Second- or Further-line Immunotherapy in Advanced Non–Small-Cell Lung Cancer: An External Validation
2020-01-01 Prelaj, A.; Lo Russo, G.; Proto, C.; Signorelli, D.; Ferrara, R.; Galli, G.; De Toma, A.; Randon, G.; Pagani, F.; Trevisan, B.; Ganzinelli, M.; Zilembo, N.; Montrone, M.; Longo, V.; Pesola, F.; Pizzutilo, P.; Del Bene, G.; Varesano, N.; Galetta, D.; Torri, V.; Garassino, M. C.; Di Maio, M.; Catino, A.
EPSILoN: A Prognostic Score Using Clinical and Blood Biomarkers in Advanced Non–Small-cell Lung Cancer Treated With Immunotherapy
2020-01-01 Prelaj, A.; Rebuzzi, S. E.; Pizzutilo, P.; Bilancia, M.; Montrone, M.; Pesola, F.; Longo, V.; Del Bene, G.; Lapadula, V.; Cassano, F.; Petrillo, P.; Bafunno, D.; Varesano, N.; Lamorgese, V.; Mastrandrea, A.; Ricci, D.; Catino, A.; Galetta, D.
Gastrointestinal stromal tumors and second primary malignancies: a retrospective monocentric analysis
2020-01-01 Comandini, D; Grassi, M; Prelaj, A; Martelli, V; Damiani, A; Damiano, G; Rebuzzi, S Elena
Treatment patterns among patients with malignant pleural mesothelioma: An Italian, population-based nationwide study
2020-01-01 Trama, A.; Proto, C.; Signorelli, D.; Garassino, M. C.; Lo Russo, G.; Ganzinelli, M.; Prelaj, A.; Mensi, C.; Gangemi, M.; Gennaro, V.; Chellini, E.; Caldarella, A.; Angelillo, I. F.; Ascoli, V.; Pascucci, C.; Tagliabue, G.; Cusimano, R.; Bella, F.; Falcini, F.; Merler, E.; Masanotti, G.; Ziino, A.; Michiara, M.; Gola, G.; Storchi, C.; Mangone, L.; Vitale, M. F.; Cirilli, C.; Tumino, R.; Scuderi, T.; Fanetti, A. C.; Piffer, S.; Tiseo, M.; Gatta, G.; Botta, L.
Immunotherapy beyond progression in patients with advanced non-small cell lung cancer
2020-01-01 Ge, X.; Zhang, Z.; Zhang, S.; Yuan, F.; Zhang, F.; Yan, X.; Han, X.; Ma, J.; Wang, L.; Tao, H.; Li, X.; Zhi, X.; Huang, Z.; Hofman, P.; Prelaj, A.; Banna, G. L.; Mutti, L.; Hu, Y.; Wang, J.
Relationship Between Programmed Death Receptor-Ligand 1 Expression and Response to Checkpoint Inhibitor Immunotherapy in Pulmonary Sarcomatoid Carcinoma: A Pooled Analysis
2020-01-01 Babacan, N. A.; Pina, I. B.; Signorelli, D.; Prelaj, A.; Garassino, M. C.; Tanvetyanon, T.
Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access program
2021-01-01 Prelaj, A.; Bottiglieri, A.; Proto, C.; Lo Russo, G.; Signorelli, D.; Ferrara, R.; Galli, G.; De Toma, A.; Viscardi, G.; Brambilla, M.; Lobefaro, R.; Nichetti, F.; Manglaviti, S.; Occhipinti, M.; Labianca, A.; Ganzinelli, M.; Gallucci, R.; Zilembo, N.; Greco, G. F.; Torri, V.; de Braud, F.; Garassino, M. C.
Immunotherapy in advanced Non-Small Cell Lung Cancer patients with poor performance status: The role of clinical-pathological variables and inflammatory biomarkers
2021-01-01 Lobefaro, R.; Viscardi, G.; Di Liello, R.; Massa, G.; Iacovino, M. L.; Sparano, F.; Della Corte, C. M.; Ferrara, R.; Signorelli, D.; Proto, C.; Prelaj, A.; Galli, G.; De Toma, A.; Brambilla, M.; Ganzinelli, M.; Trevisan, B.; Ciardiello, F.; De Braud, F.; Morgillo, F.; Garassino, M. C.; Lo Russo, G.
Successful treatment of triple EGFR mutation T785A/L861Q/H297_E298 with afatinib
2021-01-01 Longo, Vito; Catino, Annamaria; Montrone, Michele; Pizzutilo, Pamela; Pesola, Francesco; Marech, Ilaria; Capone, Iolanda; Prelaj, Arsela; Galetta, Domenico
Novel patterns of progression upon immunotherapy in other thoracic malignancies and uncommon populations
2021-01-01 Ferrara, Roberto; Signorelli, Diego; Proto, Claudia; Prelaj, Arsela; Garassino, Marina Chiara; Lo Russo, Giuseppe
Carcinomatosis under control by osimertinib in EGFR and TP53 mutated lung adenocarcinoma
2021-01-01 Provenzano, Leonardo; Cuccarini, Valeria; Platania, Marco; Canziani, Luca; Spagnoletti, Andrea; Doniselli, Fabio M; Eoli, Marica; Prelaj, Arsela; Anghileri, Elena
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile